Researchers from Kazakh National Agrarian Research University engineered a monoclonal antibody delivered intranasally to block mugwort pollen allergens, effectively reducing hay fever and asthma symptoms in sensitized mice. Published in Frontiers in Immunology, this first-in-vivo evidence highlights potential for fast-acting, needle-free, allergen-specific allergy treatments. The approach offers promise for precision therapies targeting major aeroallergens, addressing the rising prevalence of pollen-induced allergic diseases across Europe and beyond.